Clinical Trial

A Study of F8IL10 Intra-articular Treatment in Rheumatoid Arthritis

Study acronym: DekaJoint
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The aim of this study is to evaluate the safety of F8IL10 when administered by intra-articular injection and to determine the maximum tolerated dose (MTD) in order to establish the recommended dose (RD) in patients with Reumatoid Arthritis.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-17.
Status change: Not Yet Recruiting → Recruiting 2026-01-07
Trial Details
NCT Number NCT07245992
Lead Sponsor Philogen S.p.A.
Conditions Rheumatoid Arthritis (RA)
Enrollment 42 participants
Start Date 2026-03-04
Primary Completion 2028-09-30 (estimated)
Study Completion 2029-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-11